Airborne Fine Particulate Matter (PM 10) in Southeast Chicago

published or submitted for publicationis peer reviewedOpe

Surface Dust Elemental Profiles--Granite City

published or submitted for publicationis peer reviewedOpe

Surface Dust Elemental Profiles--Oglesby (Cement Plant)

published or submitted for publicationis peer reviewedOpe

Temporal Characteristics of Airborne Particulate Matter in Phnom Penh, Cambodia

Particulate matter of less than 10 microns (PM-10), has been identified as a critical airborne pollutant of most Asian cities, and is often attributed to vehicle traffic. PM-10 is not routinely monitored in Phnom Penh, Cambodia. Using a particle counter, PM-10 was monitored along Phnom Penh roads creating road-side temporal profiles. The 'commuter profile' exhibited high PM-10 counts in the morning and late afternoon. The 'business district profile' exhibited high PM-10 counts in the late-morning/early-afternoon. The PM-10 particle counts were converted to PM-10 mass measurements (µg/m3). The PM-10 mass measurements exceeded the WHO daily standard of 50 µg/m3, while it approached and sometimes exceeded (during periods of peak traffic) the U.S. EPA standard of 150 µg/m3

Development of a Particulate Filter Standard and Its Use in an International Atomic Energy Agency: Interlaboratory Evaluation

published or submitted for publicationis peer reviewedOpe

Surface Dust Elemental Profiles--Southeast Chicago (Lake Calumet and McCook Areas)

published or submitted for publicationis peer reviewedOpe

Airborne Fine Particulate Matter (PM-10) in Southeast Chicago

published or submitted for publicationis peer reviewedOpe

Atmospheric Deposition of Toxic Materials: A Component of the Green Bay Mass Balance Study

published or submitted for publicationis peer reviewedOpe

A Multi-Arm Phase I Study of the PI3K/mTOR Inhibitors PF-04691502 and Gedatolisib (PF-05212384) plus Irinotecan or the MEK Inhibitor PD-0325901 in Advanced Cancer

Ajuts: This study was sponsored by Pfizer Inc.This phase I, four-arm, open-label study (NCT01347866) evaluated the PI3K/mTOR inhibitors PF-04691502 (arms A, B) and gedatolisib (PF-05212384; arms C, D) in combination with the MEK inhibitor PD-0325901 (arm A, D) or irinotecan (arm B, C) in patients with advanced solid tumors. Primary endpoint was dose-limiting toxicity with each combination. Secondary endpoints included safety, pharmacokinetics and preliminary antitumor activity. Dose escalation followed a 3 + 3 design in arm C and a zone-based design in arm D. The PF-04691502 combination arms were closed prematurely due to low tolerability, and the maximum tolerated doses (MTDs) were not determined for either arm. The MTD for the combination of gedatolisib with irinotecan 180 mg/m 2 was estimated to be 110 mg weekly and for the combination with PD-0325901 was not reached at the highest dose evaluated (gedatolisib 154 mg weekly). Plasma concentrations of gedatolisib were generally similar across dose groups in arm C (with irinotecan) and arm D (with PD-0325901). Frequent dose delays or dose reductions were required for both combinations, potentially preventing sustained therapeutic drug concentrations. Gedatolisib plus irinotecan produced a response rate of ~5% and clinical benefit in 16% of patients with advanced colorectal cancer (progression-free survival, 2.8 months). Preliminary evidence of clinical activity was observed with gedatolisib plus PD-0325901 in patients with ovarian cancer (three partial responses, n = 5) or endometrial cancer (one partial response, n = 1) and KRAS mutations. Further evaluations of gedatolisib are warranted in patients with advanced solid malignancies. The online version of this article (10.1007/s11523-017-0530-5) contains supplementary material, which is available to authorized users

Toxic Volatile Organic Chemicals in Urban Air in Illinois

HWRIC project number 9000